CClinicalTrials.gg
CompletedNCT06738524Updated Dec 17, 2024

Digital Addiction, Sleep Quality and Orexin-A Level

An interventional study of Fighting with Digital Addiction in Digital Addiction, sponsored by Amasya University. Completed at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Amasya University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Feb 2024, registered Dec 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Sex
All
01

Study summary

This study aims to determine the level of digital addiction in university students where technology use is quite common, and to evaluate the relationship between digital addiction and orexin and sleep quality.

The main question it aims to answer is:

  • Are digital addiction trainings given to students effective on digital addiction levels?
  • Are digital addiction trainings given to students effective on sleep quality?
  • Is there a relationship between digital addiction level and orexin-A peptide?
Read the detailed description

The changes experienced in technology along with the developing world also bring about major changes in the lives of individuals. It is seen that technology is present in every aspect of life, especially the internet that enables widespread communication and the use of the tools and equipment developed accordingly is rapidly increasing especially in the young age group. It is stated that digital addiction is spreading very rapidly throughout the world and has many negative consequences on the daily life and health of the individual. Many health problems such as personality disorders, violence, increase in aggressive behavior, disruptions in the sleep-wake cycle, anxiety, and depression are associated with digital addiction. Orexins are hypothalamic neuropeptides that play a role in the regulation of many complex behaviors such as nutrition, sleep, and wakefulness. In recent studies, it is thought that orexin can cause behavioral addictions. Orexin plays a role in both the early and late stages of the addiction mechanism.

02

Conditions studied

  • Digital Addiction

Browse trials for

Keywords

  • Digital addiction
  • Orexin-A
  • Sleep quality
  • Technology
03

In context

Behavior, Addictive

540 studies on the registry are indexed under Behavior, Addictive; 134 are open to participants now.

This study's enrollment of 42 is below the median of 72 across 391 interventional studies indexed under Behavior, Addictive.

Browse Behavior, Addictive studies →

Lead sponsor

Amasya University is the lead sponsor of 78 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Individuals studying at Amasya University,
  • Those who agree to participate in the study,
  • Individuals who do not have any communication barriers

Exclusion criteria

Exclusion Criteria:

  • Individuals who are not students at Amasya University,
  • Individuals with communication disabilities.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Education

    The intervention group was given "Fighting with Digital Addiction" training.

    Behavioral: Fighting with Digital Addiction

Interventions

  • BehavioralFighting with Digital Addiction

    The purpose of this training is to raise awareness among young people about the signs, causes and consequences of addictive use of technology and how to avoid excessive use of technology and technology addiction.

06

What researchers measure

Primary outcomes

  1. Digital Addiction Scale

    A positive change in participants' digital addiction scores is expected at the end of the training program.

    Time frame: 4 weeks.

07

Study locations

1 site
  • Amasya University
    Amasya, Merkez 05200, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06738524
Lead sponsor
Amasya University
Responsible party
Zehra Incedal Sonkaya (Asst. Prof., Amasya University) — Principal investigator
First posted
Dec 17, 2024
Start date
Feb 1, 2024
Primary completion
Jun 1, 2024
Completion
Aug 1, 2024
Last update
Dec 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion